Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Nuveen Asset Management LLC trimmed its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 69.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,485 shares of the company's stock after selling 181,863 shares during the quarter. Nuveen Asset Management LLC owned about 0.20% of Keros Therapeutics worth $1,258,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Braidwell LP raised its position in Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Lynx1 Capital Management LP bought a new position in shares of Keros Therapeutics during the 4th quarter valued at about $8,612,000. Millennium Management LLC grew its stake in shares of Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock worth $13,901,000 after purchasing an additional 305,169 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of Keros Therapeutics in the 4th quarter worth approximately $3,958,000. Finally, Integral Health Asset Management LLC raised its holdings in shares of Keros Therapeutics by 125.0% in the 4th quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company's stock worth $7,124,000 after purchasing an additional 250,000 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now directly owns 4,392,737 shares of the company's stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 20.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on KROS shares. Truist Financial reduced their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Scotiabank reduced their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. Wedbush reaffirmed a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Friday, May 30th. HC Wainwright reduced their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Wells Fargo & Company decreased their price target on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.00.

Keros Therapeutics Trading Down 0.5%

NASDAQ KROS traded down $0.07 during trading on Friday, reaching $15.04. 739,298 shares of the company's stock were exchanged, compared to its average volume of 849,113. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The company's fifty day simple moving average is $13.33 and its 200-day simple moving average is $18.52. The firm has a market capitalization of $610.85 million, a PE ratio of -2.89 and a beta of 1.31.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping the consensus estimate of ($0.01) by $3.63. The business had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. During the same period last year, the company posted ($1.21) earnings per share. Equities analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.